Literature DB >> 22126734

Transthoracic oesophagectomy with lymphadenectomy in 100 oesophageal cancer patients: multidisciplinary approach.

V Valentí1, J L Hernández-Lizoain, F Marínez-Regueira, M Bellver, J Rodríguez, J A Díaz González, W Torres, J J Sola, J Alvarez-Cienfuegos.   

Abstract

OBJECTIVES Analysis of the results on the treatment of esophageal cancer by transthoracic esophagectomy by a multidisciplinary team of surgeons and oncologists. METHODS Between January 1990 and December 2009, 100 consecutive patients underwent transthoracic esophagectomy. Data were collected prospectively and clinical, pathological and histological features of the tumors were analyzed as well as the results of postoperative morbidity and mortality. RESULTS The average patient age was 55 years (range 31- 83 years). In 59 cases the tumor was located in the lower third and in 41 cases in the middle third. Forty-six patients had adenocarcinoma and 54 squamous cell carcinoma. In 54 cases radio-chemotherapy was planned preoperatively. Classifi cation according to pathological tumor stage was: stage 0 in 21 patients, stage I in 10 patients, stage IIa in 28, stage IIb in 9, stage III in 21 and stage IV in 11. The mean number of lymph nodes examined was 14 (range 0-28). Hospital mortality occurred in 4 cases and postoperative complications in 29 patients (33%). The most frequent postoperative complication was pulmonary complications in 17 cases. The average hospital stay was 15.2 days (range 10-40 days) CONCLUSIONS The results of esophageal cancer have been improved in recent years due to the formation of multidisciplinary teams in this pathology. In our study we have shown that the results obtained with the transthoracic technique for cancer of the esophagus are within the ranges reported in the literature for teams with high prevalence of the disease.

Entities:  

Mesh:

Year:  2011        PMID: 22126734     DOI: 10.1007/s12094-011-0752-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  24 in total

1.  Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.

Authors:  J D Luketich; D M Friedman; T L Weigel; M A Meehan; R J Keenan; D W Townsend; C C Meltzer
Journal:  Ann Thorac Surg       Date:  1999-10       Impact factor: 4.330

2.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

3.  A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma.

Authors:  K M Chu; S Y Law; M Fok; J Wong
Journal:  Am J Surg       Date:  1997-09       Impact factor: 2.565

4.  POSSUM and Portsmouth POSSUM for predicting mortality. Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity.

Authors:  D R Prytherch; M S Whiteley; B Higgins; P C Weaver; W G Prout; S J Powell
Journal:  Br J Surg       Date:  1998-09       Impact factor: 6.939

Review 5.  The importance of PET in the diagnosis and response evaluation of esophageal cancer.

Authors:  K Ott; W Weber; J-R Siewert
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

6.  Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus.

Authors:  M Adham; J Baulieux; F Mornex; E de La Roche de Bransat; C Ducerf; J C Souquet; J P Gerard
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

7.  Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus.

Authors:  C Hennequin; B Gayet; A Sauvanet; A Blazy; T Perniceni; Y Panis; F Mal; E Sarfati; P Valleur; J Belghiti; F Fekete; C Maylin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

8.  Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.

Authors:  Daniel King Hung Tong; Simon Law; Dora Lai Wan Kwong; Kwok Wah Chan; Alfred King Yin Lam; Kam Ho Wong
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

9.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.

Authors:  Karen Becker; James D Mueller; Christoph Schulmacher; Katja Ott; Ulrich Fink; Raymonde Busch; Knut Böttcher; J Rüdiger Siewert; Heinz Höfler
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

10.  Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).

Authors:  M van Heijl; J J B van Lanschot; L B Koppert; M I van Berge Henegouwen; K Muller; E W Steyerberg; H van Dekken; B P L Wijnhoven; H W Tilanus; D J Richel; O R C Busch; J F Bartelsman; C C E Koning; G J Offerhaus; A van der Gaast
Journal:  BMC Surg       Date:  2008-11-26       Impact factor: 2.102

View more
  4 in total

1.  Multidisciplinary approach to oesophageal cancer.

Authors:  F López
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

2.  Risk factors for pulmonary complications after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Masayuki Watanabe; Yoshifumi Baba; Shiro Iwagami; Takatsugu Ishimoto; Masaaki Iwatsuki; Yasuo Sakamoto; Yuji Miyamoto; Nobuyuki Ozaki; Hideo Baba
Journal:  Surg Today       Date:  2013-04-14       Impact factor: 2.549

3.  Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma.

Authors:  K Fakhrian; M Oechsner; S Kampfer; T Schuster; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

4.  Original scoring system for predicting postoperative morbidity after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Yoshifumi Baba; Masayuki Watanabe; Satoshi Ida; Takatsugu Ishimoto; Ryuichi Karashima; Shiro Iwagami; Yu Imamura; Yasuo Sakamoto; Yuji Miyamoto; Hideo Baba
Journal:  Surg Today       Date:  2014-07-06       Impact factor: 2.549

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.